drugset
Drugs / Izuforant
last change May 2024 re-read 3 minutes ago

Izuforant

also known as LEO 152020

Small molecule

Developed for
cholinergic urticaria
Investigated by
JW Pharmaceutical · LEO Pharma

Trials 1

today NCT04853992 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04853992 May 2021 → Jul 2022 cholinergic urticaria JW Pharmaceutical Completed Missed primary

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-10-20 JW Pharmaceutical Results [JW중외제약] 레오파마, 아토피 신약후보물질 권리 JW중외제약에 반환 jw-pharma.co.kr ↗
레오파마는 “레오파마가 진행해 최근 완료된 ‘이주포란트(LEO 152020)’의 글로벌 임상 2a/b상 초기 주요결과에서 일차 평가 지표를 충족하지 못했다”며 알려왔다.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Izuforant “Izuforant (LEO 152020) is a selective oral H4R antagonist with expected dual antipruritic and anti-inflammatory effects.” PMID 38308655 ↗ May 2024
Known as LEO 152020 “Izuforant (LEO 152020) is a selective oral H4R antagonist with expected dual antipruritic and anti-inflammatory effects.” PMID 38308655 ↗ May 2024
Action Inhibit “LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R).” NCT04853992 ↗
Modality Small molecule “LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R).” NCT04853992 ↗
Route Oral “LEO 152020 is a tablet for oral administration.” NCT04853992 ↗